Arachidonate metabolic pathway enzymes (AA pathway enzymes) (AA pathway enzymes)

The arachidonate metabolic pathway enzymes comprise a complex network of proteins responsible for converting arachidonic acid into potent lipid mediators known as eicosanoids (Hanna & Haeggström, 2011). This cascade typically begins with the release of arachidonic acid from cell membrane phospholipids, a process primarily catalyzed by phospholipase A2 (PLA2) (Dennis & Norris, 2011). Once released, the free arachidonic acid is metabolized through three main enzymatic branches: the cyclooxygenase (COX) pathway, the lipoxygenase (LOX) pathway, and the cytochrome P450 (CYP) pathway (Wang et al., 2021). These pathways produce a variety of bioactive molecules, including prostaglandins, thromboxanes, leukotrienes, and epoxyeicosatrienoic acids, which regulate critical physiological processes such as inflammation, pain, fever, and vascular tone (Zhou et al., 2020). Dysregulation of these enzymes is a hallmark of numerous pathological conditions, including rheumatoid arthritis, asthma, and cardiovascular disease. As a result, these enzymes are major therapeutic targets; for instance, NSAIDs inhibit COX enzymes to alleviate pain and inflammation, while 5-LOX inhibitors are used in the management of asthma (StatPearls, 2023). The complexity of this pathway necessitates careful pharmacological intervention to balance therapeutic efficacy with potential side effects like gastrointestinal or cardiovascular toxicity.

Other names

Arachidonic acid cascade enzymesEicosanoid biosynthetic enzymesAA metabolism enzymes

Inhibition of cyclooxygenase (COX-1 and COX-2) enzymes to reduce the production of pro-inflammatory prostaglandins and thromboxanes; inhibition of 5-lipoxygenase (5-LOX) to prevent leukotriene synthesis; and inhibition of phospholipase A2 (PLA2) to block the release of arachidonic acid from membrane phospholipids (Dennis & Norris, 2011; StatPearls, 2023).